Global Colorectal Cancer Market: Industry Analysis & Outlook (2021-2025)
- Report Description Table of Contents
Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine). A cancer is the abnormal growth of cells that has the ability to invade or spread to other parts of the body. Signs and symptoms for this cancer may include blood in the stool, a change in bowel movements, weight loss, and feeling tired all the time. The current screening regime for this disease comprises of gFOBT, FIT, flexible Sigmoidoscopy, Colonoscopy and others. Further, the treatment for CRC is limited to surgery, chemotherapy and radiotherapy or adjuvant therapies.
The global CRC market would be driven by factors such as rising geriatric population, better reimbursement policies, growing number of obese people and others. However, the dynamics such as stringent regulatory norms, side effects of therapies and high cost of screening tests or drugs are expected to act as a threat for market’s growth. Rising awareness regarding the incidence of CRC and importance of diagnosis has propelled higher compliance with regular tests. Further, in order to harness the market potential, various companies are involved in developing lesser invasive and easy to use screening methods.
The report “Global Colorectal Cancer Market: Industry Analysis & Outlook (2021-2025)” provides a comprehensive study of global market and also major regional markets. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in-depth. The global market is highly competitive consisting of several large enterprises including Bayer AG, Roche Holding AG, Merck & Co., Inc. and Eli Lilly and Company. The competitive landscape of the respective market, along with the company profiles of leading players are discussed in detail.